Prenetics Global Limited (PRE)

NASDAQ: PRE · IEX Real-Time Price · USD
5.80
-0.04 (-0.62%)
At close: May 17, 2024, 3:56 PM
5.78
-0.02 (-0.41%)
After-hours: May 17, 2024, 4:00 PM EDT
-0.62%
Market Cap 69.64M
Revenue (ttm) 21.74M
Net Income (ttm) -62.72M
Shares Out 12.22M
EPS (ttm) -5.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,499
Open 5.76
Previous Close 5.84
Day's Range 5.70 - 5.92
52-Week Range 2.85 - 15.00
Beta -0.28
Analysts Buy
Price Target 9.00 (+55.07%)
Earnings Date Jun 3, 2024

About PRE

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Glob... [Read more]

Sector Healthcare
Founded 2014
Employees 400
Stock Exchange NASDAQ
Ticker Symbol PRE
Full Company Profile

Financial Performance

In 2023, PRE's revenue was $21.74 million, an increase of 65.17% compared to the previous year's $13.16 million. Losses were -$62.72 million, -67.07% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PRE stock is "Buy" and the 12-month stock price forecast is $9.0.

Price Target
$9.0
(55.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results

HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced unaudited financ...

6 weeks ago - GlobeNewsWire

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

(From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dub...

3 months ago - GlobeNewsWire

Prenetics Announces Third Quarter 2023 Financial Results

HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results...

6 months ago - GlobeNewsWire

Prenetics Global Limited Announces Reverse Stock Split

HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split o...

7 months ago - GlobeNewsWire

Prenetics Announces Second Quarter 2023 Financial Results

HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial result...

8 months ago - GlobeNewsWire

Prenetics CEO discusses $200 million JV for early cancer detection breakthrough

Danny Yeung, CEO of Hong Kong's genetics testing firm Prenetics, speaks about the $200 million joint venture that his company has formed with professor Dennis Lo from Chinese University of Hong Kong, ...

11 months ago - CNBC International TV

Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening

Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT Company will Host Conference Call to Discuss the Transaction on June 26 at 8:30 a.m. EDT

11 months ago - GlobeNewsWire

Prenetics Announces First Quarter 2023 Financial Results

HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial results...

1 year ago - GlobeNewsWire

Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results

New Business Strategy Focused on Precision Oncology New Business Strategy Focused on Precision Oncology

1 year ago - GlobeNewsWire

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

LONDON and HONG KONG, March 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scien...

1 year ago - GlobeNewsWire

Prenetics to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate vi...

1 year ago - GlobeNewsWire

Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA

LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure the ...

1 year ago - GlobeNewsWire

Prenetics Global's stock rallies 82%

Shares of Prenetics Global Ltd. PRE, -2.11% jumped about 82% in premarket trading on Tuesday after the company said ActOnco's genomic test for tumors recently received clearance from the Food and Drug...

1 year ago - Market Watch

Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors

LONDON and HONG KONG, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics ...

1 year ago - GlobeNewsWire

Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology

LONDON and HONG KONG, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that it is acquiring a majority stake in ACT...

1 year ago - GlobeNewsWire

Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index

LONDON and HONG KONG, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced that i...

1 year ago - GlobeNewsWire

Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance

LONDON and HONG KONG, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its un...

1 year ago - GlobeNewsWire

Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook

LONDON and HONG KONG, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its u...

1 year ago - GlobeNewsWire

Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker “PRE.”

LONDON and HONG KONG, June 06, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its un...

2 years ago - GlobeNewsWire

Prenetics Rings the Opening Bell and Debuts on Nasdaq

LONDON and HONG KONG, May 18, 2022 (GLOBE NEWSWIRE) -- Prenetics Group Limited ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, and Artisan Acquisition Corp. (Nasdaq:...

2 years ago - GlobeNewsWire